Month: September 2025

Recent Purchases include 1,087 ETH at an Average Price of $4,598  Charlotte, NC, Sept. 19, 2025 (GLOBE NEWSWIRE) — FG Nexus (Nasdaq: FGNX, FGNXP) (the “Company”), today announced that its current ETH position increased to 49,715 ETH as of September 18, 2025, following a series of additional purchases and reflecting the positive impact of the Company’s initial staking rewards. The Company’s total ETH holdings are 49,715 representing approximately $229 million in aggregate value (assuming $4,598 price of ETH per Bloomberg as of 4:15pm ET). The Company’s strategic plan is to be the largest ETH holder in the Ethereum network. “Ethereum stands as the premier programmable asset for institutional reserves, and we’re executing on our strategy to be the dominant corporate stakeholder,” said Maja Vujinovic, CEO of Digital Assets, FG...

DAYTONA BEACH, Fla., Sept. 19, 2025 (GLOBE NEWSWIRE) — TopBuild Corp., (NYSE:BLD) a leading installer of insulation and commercial roofing and a specialty distributor of insulation and related building material products to the construction industry in the United States and Canada, will host an Investor Day in New York City on Tuesday, December 9, 2025, beginning at 8:00 a.m. ET. TopBuild President and CEO Robert Buck, CFO Rob Kuhns, and other members of the senior leadership team will present an in-depth overview of the Company, its proven business model, growth drivers, capital allocation strategy and long-term financial targets. The event will also include Q&A sessions and lunch, where in-person attendees will have the opportunity to interact with management and learn more about the business. A formal invitation to register...

MONTREAL, Sept. 19, 2025 (GLOBE NEWSWIRE) — In his role as Senior Director, Global Risk Management and Insurance at Bombardier, Daniel Desjardins has shaped the risk management and insurance landscape, as well as Bombardier’s journey, in profound ways. This week, the Risk and Insurance Management Society (RIMS) recognized that impact by presenting him with the Donald M. Stuart award, Canada’s highest honour within the risk management field. Few individuals leave a legacy as enduring as Daniel’s. Over the past 40 years, he has consistently demonstrated leadership, strong work ethic and an unwavering commitment to excellence—both within the insurance community and across Bombardier. Daniel played a pivotal role in Bombardier’s successful turnaround, offering unmatched expertise, strategic clarity and steady guidance during a defining...

REYKJAVIK, Iceland, Sept. 19, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd. (“Fuji Pharma”), has received marketing approval for three new biosimilars from the Japanese Ministry of Health, Labor and Welfare. The biosimilars approved for the Japanese market are AVT03, a biosimilar to Ranmark® (denosumab), AVT05, a biosimilar to Simponi® (golimumab) and AVT06, a biosimilar to Eylea® (aflibercept). Based on publicly available information, AVT05 is the first golimumab biosimilar to be approved for sale in major markets globally. “We are thrilled to receive marketing approvals for three additional biosimilars in Japan, after our...

REYKJAVIK, ICELAND (September 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd. (“Fuji Pharma”), has received marketing approval for three new biosimilars from the Japanese Ministry of Health, Labor and Welfare. The biosimilars approved for the Japanese market are AVT03, a biosimilar to Ranmark® (denosumab), AVT05, a biosimilar to Simponi® (golimumab) and AVT06, a biosimilar to Eylea® (aflibercept). Based on publicly available information, AVT05 is the first golimumab biosimilar to be approved for sale in major markets globally. “We are thrilled to receive marketing approvals for three additional biosimilars in Japan, after our successful launch last...

VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) — 1911 Gold Corporation (“1911 Gold” or the “Company”) (TSXV: AUMB; OTCQB: AUMBF; FRA: 2KY) is pleased to announce that it has entered into an agreement with Haywood Securities Inc. (“Haywood”), as lead agent and sole bookrunner, on its own behalf and on behalf of a syndicate of agents (together with Haywood, the “Agents”), pursuant to which the Agents have agreed to sell, on a “best efforts” private placement basis, any combination of: common shares of the Company (the “LIFE Non-FT Shares”) at a price per LIFE Non-FT Share of C$0.45 (the “Non-FT Issue Price”); (ii) common shares which qualify as “flow-through shares” (within the meaning of the Tax Act) and qualify as “Canadian exploration expenses” as defined in the Tax Act (the “CEE Offered Shares”) at a...

19 September 2025 Invitation to Netcompany’s Capital Markets Day 31 October 2025 – Unlocking the Potential Netcompany is pleased to invite investors, analysts, and media representatives to the company’s Capital Markets Day on Friday 31 October 2025 at 11.15 CET. The purpose of the event is to share insights on Netcompany’s 2030 strategy and how we will utilise our products and platforms to unlock the growth potential in Europe. We will also provide a presentation on Netcompany Banking Services (previously SDC) and expected synergies as well as our 2030 financial aspirations. Venue The Capital Markets Day will take place 31 October 2025 in Netcompany’s Corporate Headquarters in Copenhagen at Strandgade 3 from 11.15 to 16.15 CET. The event will be a hybrid event facilitating participation both physically and virtually. Sign-up Please...

KH Group PlcInside information, 19 September 2025 at 12:45 pm EEST Inside information, profit warning: KH Group Plc lowers its profit guidance for 2025 KH Group Plc lowers its profit guidance for 2025. In the 2024 Financial Statements Release published on 21 March 2025, the company estimated that both the net sales (EUR 194.0 million) and the comparable operating profit (EUR 7.2 million) will remain approximately at the same level year-on-year. According to the updated guidance, the company estimates, with the continuing operations Group structure, to reach net sales of EUR 190–200 million and comparable operating profit of EUR 5–6 million in 2025. The lowering of the guidance is based on an estimate of weaker operating profit in the largest business area KH-Koneet. The company will publish its January–September 2025 Business Review...